X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs IPCA LABS - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB IPCA LABS DR. REDDYS LAB/
IPCA LABS
 
P/E (TTM) x 27.9 27.5 101.3% View Chart
P/BV x 2.9 2.1 136.1% View Chart
Dividend Yield % 1.0 0.2 405.0%  

Financials

 DR. REDDYS LAB   IPCA LABS
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-16
IPCA LABS
Mar-17
DR. REDDYS LAB/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs4,383643 681.6%   
Low Rs2,750503 546.9%   
Sales per share (Unadj.) Rs920.1254.4 361.7%  
Earnings per share (Unadj.) Rs126.116.1 784.7%  
Cash flow per share (Unadj.) Rs183.029.8 614.6%  
Dividends per share (Unadj.) Rs20.001.00 2,000.0%  
Dividend yield (eoy) %0.60.2 321.3%  
Book value per share (Unadj.) Rs685.8194.6 352.5%  
Shares outstanding (eoy) m170.61126.20 135.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.92.3 172.1%   
Avg P/E ratio x28.335.7 79.3%  
P/CF ratio (eoy) x19.519.2 101.3%  
Price / Book Value ratio x5.22.9 176.6%  
Dividend payout %15.96.2 254.9%   
Avg Mkt Cap Rs m608,48172,300 841.6%   
No. of employees `00021.713.3 162.9%   
Total wages/salary Rs m31,8746,960 458.0%   
Avg. sales/employee Rs Th7,244.42,413.5 300.2%   
Avg. wages/employee Rs Th1,470.9523.2 281.2%   
Avg. net profit/employee Rs Th992.8152.4 651.3%   
INCOME DATA
Net Sales Rs m156,97832,106 488.9%  
Other income Rs m2,693226 1,193.2%   
Total revenues Rs m159,67132,332 493.8%   
Gross profit Rs m34,5874,448 777.6%  
Depreciation Rs m9,7051,730 561.1%   
Interest Rs m824241 342.2%   
Profit before tax Rs m26,7512,703 989.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,237675 775.6%   
Profit after tax Rs m21,5142,028 1,060.8%  
Gross profit margin %22.013.9 159.0%  
Effective tax rate %19.625.0 78.4%   
Net profit margin %13.76.3 217.0%  
BALANCE SHEET DATA
Current assets Rs m118,20117,340 681.7%   
Current liabilities Rs m68,3689,559 715.2%   
Net working cap to sales %31.724.2 131.0%  
Current ratio x1.71.8 95.3%  
Inventory Days Days60100 59.8%  
Debtors Days Days9757 170.4%  
Net fixed assets Rs m72,26520,779 347.8%   
Share capital Rs m853252 338.0%   
"Free" reserves Rs m111,54824,499 455.3%   
Net worth Rs m117,00924,553 476.6%   
Long term debt Rs m10,6903,517 303.9%   
Total assets Rs m200,10439,595 505.4%  
Interest coverage x33.512.2 273.7%   
Debt to equity ratio x0.10.1 63.8%  
Sales to assets ratio x0.80.8 96.7%   
Return on assets %11.25.7 194.8%  
Return on equity %18.48.3 222.6%  
Return on capital %21.610.5 205.9%  
Exports to sales %46.348.6 95.1%   
Imports to sales %9.014.2 62.9%   
Exports (fob) Rs m72,61815,617 465.0%   
Imports (cif) Rs m14,0504,571 307.4%   
Fx inflow Rs m75,40515,617 482.8%   
Fx outflow Rs m27,1155,828 465.3%   
Net fx Rs m48,2909,790 493.3%   
CASH FLOW
From Operations Rs m40,4762,764 1,464.3%  
From Investments Rs m-19,421-1,432 1,356.5%  
From Financial Activity Rs m-17,009-1,591 1,068.9%  
Net Cashflow Rs m4,046-259 -1,563.4%  

Share Holding

Indian Promoters % 25.5 45.9 55.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 11.4 47.4%  
FIIs % 35.3 25.3 139.5%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 17.4 87.9%  
Shareholders   75,885 36,892 205.7%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   SANOFI INDIA  ABBOTT INDIA  PLETHICO PHARMA  WYETH LTD  TORRENT PHARMA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 23, 2017 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS